公开(公告)号：US10239843B2

公开(公告)日：2019-03-26

申请号：US15533804

申请日：2015-12-11

Applicant: CANCER RESEARCH TECHNOLOGY LIMITED

Inventor： Alison E. McGonagle ,  Allan Jordan ,  Bohdan Waszkowycz ,  Colin Hutton ,  Ian Waddell ,  James R. Hitchin ,  Kate Mary Smith ,  Niall M. Hamilton

IPC: A61K31/517 ,  C07D239/96 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D215/227 ,  C07D217/22 ,  C07D217/24 ,  C07D401/06 ,  C07D403/06 ,  C07D403/14 ,  C07D405/06 ,  C07D409/14 ,  C07D239/88 ,  C07D239/90 ,  C07D239/91 ,  C07D413/06 ,  C07D417/06 ,  C07D241/44 ,  C07D417/14 ,  C07D237/32 ,  C07D471/04

Abstract: The present invention relates to compounds of formula I that function as inhibitors of PARG (Poly ADP-ribose glycohydrolase) enzyme activity wherein R1a, R1b, R1c, R1d, R1e, W, X1, X2, X3, X4, X5, X6, X7, c are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which PARG activity is implicated.